Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: Post hoc analysis of patients with early Parkinson's disease with mild symptom severity

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 10, 2015, Pages 1423-1433

  Timmermann, Lars ^a   Asgharnejad, Mahnaz ^b   Boroojerdi, Babak ^b   Dohin, Elisabeth ^b   Woltering, Franz ^b   Elmer, Lawrence W ^c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UCB PHARMA   (Belgium)

^c UNIVERSITY OF TOLEDO   (United States)

Author keywords

Activities of daily living; Early Parkinson's disease; Long term efficacy; Motor control; Rotigotine transdermal patch; Unified Parkinson's Disease Rating Scale

Indexed keywords

AMANTADINE; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; ENTACAPONE; LEVODOPA; MODAFINIL; PLACEBO; ROPINIROLE; ROTIGOTINE; DOPAMINE RECEPTOR STIMULATING AGENT; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; EARLY INTERVENTION; FEMALE; HOEHN AND YAHR SCALE; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOTOR PERFORMANCE; OPEN STUDY; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHASE 3 CLINICAL TRIAL; PHYSICAL DISABILITY; POST HOC ANALYSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THERAPY DELAY; TRANSDERMAL PATCH; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE; CLINICAL TRIAL; INTRADERMAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PSYCHOLOGY; TIME; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, CUTANEOUS; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PROSPECTIVE STUDIES; TETRAHYDRONAPHTHALENES; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84933564000     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1049597     Document Type: Article

References (24)

1. Appel-Cresswell S, De la Fuente-Fernandez R, Galley S, et al. Imaging of compensatory mechanisms in Parkinson's disease. Cur Opin Neurol 2010; 23(4): 407-12
2. Maetzler W, Hausdorff JM. Motor signs in the prodromal phase of Parkinson's disease. Move Disorders 2012; 27(5): 627-33
3. Herz DM, Florin E, Christensen MS, et al. Dopamine replacement modulates oscillatory coupling between premotor and motor cortical areas in Parkinson's disease. Cereb Cortex 2014; 24(11): 2873-83
4. Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the quality standards subcommittee of the american academy of neurology. Neurology 2002; 58(1): 11-17
5. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014; 311(16): 1670-83
6. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal?. Ann Neurol 2006; 59(3): 559-62
7. Schrag A, Dodel R, Spottke A, et al. Rate of clinical progression in Parkinson's disease. A prospective study. Mov Disord 2007; 22(7): 938-45
8. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Eng J Med 2009; 361(13): 1268-78
9. Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and posthoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011; 10(5): 415-23
10. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Archiv Neurol 2004; 61(4): 561-6
11. Grosset D, Taurah L, Burn DJ, et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiat 2007; 78(5): 465-9
12. AlDakheel A, Kalia LV, Lang AE. Pathogenesis-Targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics 2014; 11(1): 6-23
13. Scheller D, Ullmer C, Berkels R, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 2009; 379(1): 73-86
14. Elshoff JP, Braun M, Andreas JO, et al. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 2012; 34(4): 966-78
15. Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007; 68(4): 272-6
16. Jankovic J, Watts RL, Martin W, et al. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007; 64(5): 676-82
17. Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007; 22(16): 2398-404
18. Elmer LW, Surmann E, Boroojerdi B, et al. Long-Term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. Parkinsonism Relat Disord 2012; 18(5): 488-93
19. Giladi N, Boroojerdi B, Surmann E. The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease. J Neural Transm 2013; 120(9): 1321-9
20. Giladi N, Ghys L, Surmann E, et al. Effects of long-Term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease. Parkinsonism Relat Disord 2014; 20(12): 1345-51
21. Oster S, Radad K, Scheller D, et al. Rotigotine protects against glutamate toxicity in primary dopaminergic cell culture. Eur J Pharmacol 2014; 724: 31-42
22. Radad K, Scheller D, Rausch WD, et al. Neuroprotective effect of rotigotine against complex I inhibitors, MPP(+)and rotenone, in primary mesencephalic cell culture. Folia Neuropathol 2014; 52(2): 179-86
23. Scheller D, Stichel-Gunkel C, Lubbert H, et al. Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease. Neurosci Lett 2008; 432(1): 30-4
24. Mestre TA, Shah P, Marras C, et al. Another face of placebo: the lessebo effect in Parkinson disease: meta-Analyses. Neurology 2014; 82(16): 1402-9